MedTrace Logo

Value of an Intrathecal Synthesis Index of Specific Antitreponema IgG for Neurosyphilis Diagnosis

NCT06152393 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 181

Last updated 2023-11-30

No results posted yet for this study

Summary

A retro-prospective case-control Swiss study was conducted to evaluate the diagnostic performance of measuring an antibody index (AI) for intrathecal synthesis of specific anti-Treponema pallidum (T. pallidum) IgG for the diagnosis of neurosyphilis.

Conditions

  • Neurosyphilis

Interventions

DIAGNOSTIC_TEST

Measure of an antibody index for intrathecal synthesis of specific anti-Treponema pallidum IgG by ELISA.

Paired CSF/serum samples from all patients were blind tested for anti-T. pallidum IgG with an ELISA containing recombinant T. pallidum proteins (Euroimmun). The AI was calculated conforming to Reiber's method (PMID 11239944) and as previously described in Alberto et al. (PMID 35138118).

Sponsors & Collaborators

  • Swiss HIV Cohort Study

    collaborator NETWORK

  • Swiss National Science Foundation

    collaborator OTHER

  • University Hospital, Geneva

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06152393 on ClinicalTrials.gov